https://researchdiscovery.drexel.edu/esploro/outputs/graduate/Efficacy-of-next-generation-BRAF-inhibitors-in/991015327414504721
Efficacy of next-generation BRAF inhibitors in differentiated thyroid carcinomas - Drexel University
The serine-threonine kinase BRAF is mutated in 50% of papillary thyroid carcinoma (PTC), the most common form of thyroid cancer. The vast majority of BRAF...
next generationbraf inhibitors
https://seguralab.duke.edu/publications/cutaneous-wound-healing-through-paradoxical-mapk-activation-by-braf-inhibitors/
Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors | Duke University -...
Apr 22, 2021 - BRAF inhibitors are highly effective therapies for the treatment of BRAF(V600)-mutated melanoma, with the main toxicity being a variety of hyperproliferative...
cutaneous wound healing
https://pubmed.ncbi.nlm.nih.gov/22256804/?dopt=Abstract
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors
Mutations in RAS, particularly HRAS, are frequent in cutaneous squamous-cell carcinomas and keratoacanthomas that develop in patients treated with vemurafenib....
squamous cell carcinomas
https://eprints.soton.ac.uk/501432/
Cardiomyocyte BRAF and type 1 RAF inhibitors promote cardiomyocyte and cardiac hypertrophy in mice...
raf inhibitors